Bone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Endocrinology Unit and Prevention and Care of Diabetes, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Orphanet J Rare Dis. 2021 Oct 9;16(1):421. doi: 10.1186/s13023-021-02053-3.
Hypoparathyroidism (HypoPT) or pseudo-hypoparathyroidism (pseudo-HypoPT) during pregnancy may cause maternal and fetal/neonatal complications. In this regard, only a few case reports or case series of pregnant or lactating women have been published. The purpose of this study was to describe clinical and biochemical course, pharmacological management, and potential adverse events during pregnancy and post-partum in pregnant women with HypoPT or pseudo-HypoPT. This was a retrospective, observational, multicenter, study involving nine Italian referral centers for endocrine diseases affiliated with the Italian Society of Endocrinology and involved in "Hypoparathyroidism Working Group".
This study identified a cohort of 28 women (followed between 2005 and 2018) with HypoPT (n = 25, 84% postsurgical, 16% idiopathic/autoimmune) and pseudo-HypoPT (n = 3). In HypoPT women, the mean calcium carbonate dose tended to increase gradually from the first to third trimester (+ 12.6%) in pregnancy. This average increase in the third trimester was significantly greater compared to the pre-pregnancy period (p value = 0.03). However, analyzing the individual cases, in 44% the mean calcium dosage remained unchanged throughout gestation. Mean calcitriol doses tended to increase during pregnancy, with a statistically significant increase between the third trimester and the pre-pregnancy period (p value = 0.02). Nevertheless, analyzing the individual cases, in the third trimester most women with HypoPT (64%) maintained the same dosage of calcitriol compared to the first trimester. Both mean calcium carbonate and calcitriol doses tended to decrease from the third trimester to the post-partum six months. Most identified women (~ 70%) did not display maternal complications and (~ 90%) maintained mean serum albumin-corrected total calcium levels within the low-to-mid normal reference range (8.5 ± 0.8 mg/dl) during pregnancy. The main complications related to pregnancy period included: preterm birth (n = 3 HypoPT women), and history of miscarriages (n = 6 HypoPT women and n = 2 pseudo-HypoPT women).
This study shows that mean serum albumin-corrected total calcium levels were carefully monitored during pregnancy and post-pregnancy, with limited evaluation of other biochemical parameters, such as serum phosphate, 24 h urinary calcium, 25-OH vitamin D, and creatinine clearance. To avoid complications in mothers affected by (HypoPT) or (pseudo-HypoPT) and offspring, intense biochemical, clinical and pharmacological monitoring during pregnancy and breastfeeding is highly recommended.
妊娠期间甲状旁腺功能减退症(HypoPT)或假性甲状旁腺功能减退症(pseudo-HypoPT)可能导致母婴/新生儿并发症。在这方面,仅发表了少数关于妊娠或哺乳期妇女的病例报告或病例系列。本研究的目的是描述 HypoPT 或 pseudo-HypoPT 孕妇的临床和生化过程、药物管理以及妊娠和产后的潜在不良事件。这是一项回顾性、观察性、多中心研究,涉及意大利内分泌疾病的 9 个参考中心,这些中心隶属于意大利内分泌学会,并参与了“甲状旁腺功能减退症工作组”。
本研究确定了一组 28 名患有 HypoPT(n=25,84%为手术后,16%为特发性/自身免疫性)和 pseudo-HypoPT(n=3)的妇女的队列。在 HypoPT 女性中,从妊娠第一到第三期,碳酸钙剂量呈逐渐增加趋势(增加 12.6%)。与妊娠前相比,这种在第三期的平均增加具有显著统计学意义(p 值=0.03)。然而,分析个别病例,44%的女性在整个妊娠期间碳酸钙的平均剂量保持不变。骨化三醇剂量在妊娠期间呈增加趋势,第三期与妊娠前相比具有统计学显著差异(p 值=0.02)。然而,分析个别病例,在第三期,大多数 HypoPT 女性(64%)与第一期相比,维持相同剂量的骨化三醇。碳酸钙和骨化三醇的平均剂量均呈从第三期到产后 6 个月下降的趋势。大多数被识别的女性(70%)没有发生母婴并发症,并且(90%)在妊娠期间维持血清白蛋白校正的总钙水平在低至中正常参考范围内(8.5±0.8mg/dl)。与妊娠相关的主要并发症包括:早产(3 名 HypoPT 女性)和流产史(6 名 HypoPT 女性和 2 名 pseudo-HypoPT 女性)。
本研究表明,在妊娠和产后期间,对血清白蛋白校正的总钙水平进行了仔细监测,对其他生化参数(如血清磷酸盐、24 小时尿钙、25-羟维生素 D 和肌酐清除率)的评估有限。为了避免受(HypoPT)或(pseudo-HypoPT)和后代影响的母亲发生并发症,强烈建议在妊娠和哺乳期进行生化、临床和药物监测。